Objective To survey the current status of community pharmacy care, analyze the needs of both community residents and medical staff for community pharmacy care, and provide references for improving the quality of communi-ty pharmacy care and policy making. Methods The form of questionnaire was taken for community residents and com-munity pharmacists from community health service centers, a random survey was conducted to collect information for statistical analysis. Results Sixty-six point eight percent of community residents selected community health service center as the main choice for obtaining drugs. The residents' home-stored drugs were mainly for cold/fever, abdominal pain/diarrhea, common chronic diseases, external wounds treating and antibacterial. Only 16.8%of community residents stored the drugs according to instructions, 70.6% would use antibacterial drug by themselves under various circum-stances, 82.8% thought there were errors in drug usage, over 98.0% of community pharmacists recognized the impor-tance of pharmaceutical care and the needs for further development. 89.1% of them were eager to improve their own capability of serving and have the needs of collaboration with large hospitals. Conclusion Improper drug usage and storage are common among community residents. Their expectations for pharmaceutical service are increasing. And community pharmacists expected to improve their own pharmacy service capability.

Objective: To improve the N biomarker in the amyloid/taueurodegeneration system by radiomics and study its value for predicting cognitive progression in individuals with mild cognitive impairment (MCI). Materials and Methods: A group of 147 healthy controls (HCs) (72 male; mean age ± standard deviation, 73.7 ± 6.3 years), 197 patients with MCI (114 male; 72.2 ± 7.1 years), and 128 patients with Alzheimer’s disease (AD) (74 male; 73.7 ± 8.4 years) were included. Optimal A, T, and N biomarkers for discriminating HC and AD were selected using receiver operating characteristic (ROC) curve analysis. A radiomics model containing comprehensive information of the whole cerebral cortex and deep nuclei was established to create a new N biomarker. Cerebrospinal fluid (CSF) biomarkers were evaluated to determine the optimal A or T biomarkers. All MCI patients were followed up until AD conversion or for at least 60 months. The predictive value of A, T, and the radiomics-based N biomarker for cognitive progression of MCI to AD were analyzed using Kaplan-Meier estimates and the log-rank test. Results: The radiomics-based N biomarker showed an ROC curve area of 0.998 for discriminating between AD and HC. CSF Aβ42 and p-tau proteins were identified as the optimal A and T biomarkers, respectively. For MCI patients on the Alzheimer’s continuum, isolated A+ was an indicator of cognitive stability, while abnormalities of T and N, separately or simultaneously, indicated a high risk of progression. For MCI patients with suspected non-Alzheimer’s disease pathophysiology, isolated T+ indicated cognitive stability, while the appearance of the radiomics-based N+ indicated a high risk of progression to AD. Conclusion We proposed a new radiomics-based improved N biomarker that could help identify patients with MCI who are at a higher risk for cognitive progression. In addition, we clarified the value of a single A/T/N biomarker for predicting the cognitive progression of MCI.